Zimmer Biomet Holdings, Inc. has entered into a new financing agreement as of June 27, 2025. The company has secured a five-year revolving credit facility valued at $1.5 billion through an agreement with JPMorgan Chase Bank, N.A., acting as the administrative agent, along with other lenders. This Five-Year Revolving Credit Agreement, which is unsecured, includes options for two one-year extensions, subject to lender consent. Additionally, Zimmer Biomet has the ability to request an increase of the facility by up to $500 million. The funds will be utilized for general corporate purposes, with interest rates set at floating rates based on either an adjusted Term SOFR or an alternate base rate, plus an applicable margin. This new agreement replaces a previous five-year credit arrangement, which was terminated upon entering the new agreement.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.